Donald Steen, chairman of the board of AmeriPath, has been named chief executive officer for the Riviera Beach, Fla., company, which manages and operates pathology laboratories and provides molecular diagnostics services, AmeriPath said in a statement last week. Steen was named chairman of the company on March 22, replacing Jim New, who was chairman and CEO before retiring Feb. 1, according to SEC documents.
CeMines of Evergreen, Colo., last week named Wenpei Su as director of genomics applications. Su previously was at Dow Chemical, and before that at Torrey Mesa Research Institute, and before that, as genomic group leader with Monsanto. Su holds a PhD in molecular biology and biochemistry from Cornell University.
Ubaldo Livolsi resigned and Francesco Parenti retired from the board of directors of Vicuron Pharmaceuticals of King of Prussia, Pa., the company said last week.
David Ferrick joins Guava Technologies of Hayward, Calif., as vice president of biology and clinical applications. Ferrick previously was chief executive officer and director of Sagres Discovery of Davis, Calif., a company he co-founded in 1999. Prior to Sagres, he was director of molecular and cellular biology at Rigel Pharmaceuticals in South San Francisco. He was also an associate professor of pathology, microbiology, and immunology at the University of California, Davis. Ferrick holds a PhD in immunology from Georgetown University.
Bernard Kasten joins SIGA Technologies of New York as chief executive officer. Previously Kasten was vice president of medical affairs of the MedPlus subsidiary of Quest Diagnostics. Kasten, a member of SIGA's board of directors since May 2003, is a graduate of the Ohio State University College of Medicine.
Knud Aunstrup joins Nuevolution of Copenhagen, Denmark, as chief executive officer, replacing Zaed Subhan, who resigned for personal reasons, the company said last week. Aunstrup previously led Novo Nordisk's biotechnology division with global responsibility for R&D. He was also president of Novo Nordisk China.
Max Link, a director of Protein Design Labs since 1993, has been elected chairman of the board.